FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS for Adult Patients with Active Lupus Nephritis
LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis a condition that causes irreversible kidney damage and increases the...
U.S. Food and Drug Administration Approves OPDIVO® in Combination with CABOMETYX® as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
In CheckMate -9ER, OPDIVO in combination with CABOMETYX doubled median progression-free survival and objective response rate and showed superior overall...
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
Conference Call and Webcast to Follow – Gilead Sciences, Inc. announced today that its fourth quarter and full year 2020...
Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m.
Bristol Myers Squibb today announced that it has changed the timing of its previously announced earnings conference call. The Company...
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
U.S. Food and Drug Administration assigned a target action date of May 20, 2021 Application based on Phase 3 CheckMate...
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
U.S. Food and Drug Administration assigned a target action date of May 25, 2021 Bristol Myers Squibb today announced that...
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
Research Veteran Brings More than 30 Years of Industry and NIH Experience to Kite Leadership Team -- Kite, a Gilead...